scispace - formally typeset
M

Michael J. Rieder

Researcher at University of Western Ontario

Publications -  60
Citations -  6741

Michael J. Rieder is an academic researcher from University of Western Ontario. The author has contributed to research in topics: Medicine & Pregnancy. The author has an hindex of 33, co-authored 50 publications receiving 6052 citations. Previous affiliations of Michael J. Rieder include University of Toronto & London Health Sciences Centre.

Papers
More filters
Journal ArticleDOI

High-versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma.

TL;DR: Compared with the low-dose regimen, the high- dose regimen resulted in significantly greater improvement in forced expiratory volume in 1 second, forced vital capacity, and wheeze score and a lower hospitalization rate.
Journal ArticleDOI

A blinded, randomized controlled trial to evaluate ketamine/propofol versus ketamine alone for procedural sedation in children.

TL;DR: When compared with ketamine alone for pediatric orthopedic reductions, the combination of ketamine and propofol produced slightly faster recoveries while also demonstrating less vomiting, higher satisfaction scores, and similar efficacy and airway complications.
Journal ArticleDOI

Effectiveness and tolerability of pharmacologic and combined interventions for reducing injection pain during routine childhood immunizations: Systematic review and meta-analyses

TL;DR: Assessment of the effectiveness and tolerability of various pharmacologic and combined interventions for reducing the pain experienced by children during immunization found the use of topical local anesthetics was associated with less pain than was placebo.
Journal ArticleDOI

An alternate mechanism of glucocorticoid anti‐proliferative effect: promotion of a Th2 cytokine‐secreting profile

TL;DR: Collectively, this indicates that, in exerting their anti‐proliferative effects, GCs act indirectly by altering Th1/Th2 cytokine balance, blocking the (pro‐ inflammatory) Th1 program and favoring the (anti‐inflammatory) Th2 program.